Sodium Oxybate Tablet Coating for Rapid Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sodium oxybate treatments for conditions like narcolepsy and fibromyalgia require cumbersome administration of a highly water-soluble and hygroscopic drug, which is challenging to formulate into effective solid immediate release dosage forms that mimic the bioavailability of the oral solution.
Innovation Solution
Development of immediate release tablets with a high sodium oxybate content (70-90 wt%) that are coated with a water-resistant film, allowing for rapid dissolution within one hour, eliminating the need for high-performance disintegrants and maintaining bioequivalence with the existing oral solution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If sodium oxybate is formulated as a solid immediate release dosage form, then patient compliance and convenience are improved, but the drug's high water solubility and hygroscopicity cause formulation challenges and gel formation
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by using a non-aqueous solvent system (isopropyl alcohol and water mixture) instead of pure water, adjusting the pH to 3.0-4.0, and controlling the solvent ratio to prevent gel formation while maintaining drug solubility and stability in solid dosage form
Solution Approach 2:
The patent creates a composite formulation by combining sodium oxybate with a specific solvent system (isopropyl alcohol and water in controlled ratios), pH adjusters, and excipients to form a stable solid dosage form that overcomes the inherent properties of the drug alone
2Reliability
If the oral solution is administered, then rapid absorption and bioavailability are achieved, but the administration regimen is cumbersome and prone to errors
Solution Approach 1:
The patent transforms the liquid oral solution into a solid tablet dosage form while maintaining comparable bioavailability, changing the physical state parameter from liquid to solid and optimizing dissolution characteristics to achieve rapid absorption similar to the oral solution
Solution Approach 2:
The patent extracts the active drug substance from the complex liquid formulation and delivers it in a simplified solid tablet form, eliminating the need for liquid measurement and preparation steps while maintaining therapeutic efficacy
3Quantity of substance
If high sodium oxybate content is used in the tablet, then therapeutic effectiveness is improved, but the drug's hygroscopicity increases formulation difficulty
Solution Approach 1:
The patent achieves high drug content (70-90 wt%) by changing the formulation parameters to use a non-aqueous solvent system that prevents gel formation, allowing concentrated drug loading without the formulation failures that would occur with traditional aqueous systems
Solution Approach 2:
The patent applies different quality characteristics to different parts of the formulation system, using isopropyl alcohol as the primary solvent in specific concentrations to create localized conditions that prevent gel formation while maintaining high drug solubility and stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tablets provide a therapeutically effective and convenient delivery of sodium oxybate, improving patient compliance by ensuring rapid absorption and bioavailability similar to the oral solution, while avoiding the need for liquid administration.
Implementation Method 1
the tablet may be coated to 1-10 wt% gain with a film coating
Data Source
Figure 1~2
Figure 3~4
AI summary
The present invention provides a pharmaceutical composition, presented as a solid unit dosage form adapted for oral administration of sodium oxybate. The preferred unit dosage form is a tablet comprising a relatively high weight-percentage of sodium oxybate, in combination with a relatively small weight-percentage of total excipients. This permits the tablets to contain/deliver a pharmaceutically effective amount, e.g., about 0.5-1.5 g of sodium oxybate in each tablet with a delivery profile similar to that of the liquid form. The tablets are bioequivalent to the liquid form.